BioSight
Companies
CorMedix Inc. logo

CRMD

NASDAQPARSIPPANY, NJ
CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company commercializing DefenCath, a catheter lock solution containing taurolidine and heparin approved by the FDA for reducing catheter-related bloodstream infections in hemodialysis patients, which launched in 2024. In August 2025, CorMedix acquired Melinta Therapeutics, expanding its commercial portfolio to include six marketed infectious disease products: REZZAYO (rezafungin), MINOCIN IV (minocycline), VABOMERE (meropenem and vaborbactam), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and BAXDELA (delafloxacin), along with the cardiovascular product TOPROL-XL (metoprolol succinate), positioning the company in hospital-based anti-infectives

Price history not yet available for CRMD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar